223 related articles for article (PubMed ID: 32717433)
1. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
Gagelmann N; Ditschkowski M; Bogdanov R; Bredin S; Robin M; Cassinat B; Shahswar R; Thol F; Heuser M; Socié G; Beelen D; Triviai I; Badbaran A; Kröger N
Blood; 2019 May; 133(20):2233-2242. PubMed ID: 30760453
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Sheth AH; Vetsa S; Grimshaw A; Giri S; Podoltsev NA; Gowda L; Tamari R; Tallman MS; Rampal RK; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Oct; 27(10):873.e1-873.e13. PubMed ID: 34052505
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
5. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
8. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
[TBL] [Abstract][Full Text] [Related]
9. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.
Gupta V; Malone AK; Hari PN; Ahn KW; Hu ZH; Gale RP; Ballen KK; Hamadani M; Olavarria E; Gerds AT; Waller EK; Costa LJ; Antin JH; Kamble RT; van Besien KM; Savani BN; Schouten HC; Szer J; Cahn JY; de Lima MJ; Wirk B; Aljurf MD; Popat U; Bejanyan N; Litzow MR; Norkin M; Lewis ID; Hale GA; Woolfrey AE; Miller AM; Ustun C; Jagasia MH; Lill M; Maziarz RT; Cortes J; Kalaycio ME; Saber W
Biol Blood Marrow Transplant; 2014 Jan; 20(1):89-97. PubMed ID: 24161923
[TBL] [Abstract][Full Text] [Related]
11. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC; Pereira A; Kröger N; Beelen D; Robin M; Bornhäuser M; Angelucci E; Vitek A; Blau IW; Niittyvuopio R; Finke J; Cornelissen JJ; Passweg J; Dreger P; Petersen E; Kanz L; Sanz J; Zuckerman T; Zinger N; Iacobelli S; Hayden P; Czerw T; McLornan D; Yakoub-Agha I
Leukemia; 2021 Jan; 35(1):215-224. PubMed ID: 32286544
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021.
Bacigalupo A; Innocenti I; Rossi E; Sora F; Galli E; Autore F; Metafuni E; Chiusolo P; Giammarco S; Laurenti L; Benintende G; Sica S; De Stefano V
Front Immunol; 2021; 12():637512. PubMed ID: 34017327
[TBL] [Abstract][Full Text] [Related]
15. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.
Tamari R; McLornan DP; Ahn KW; Estrada-Merly N; Hernández-Boluda JC; Giralt S; Palmer J; Gale RP; DeFilipp Z; Marks DI; van der Poel M; Verdonck LF; Battiwalla M; Diaz MA; Gupta V; Ali H; Litzow MR; Lazarus HM; Gergis U; Bashey A; Liesveld J; Hashmi S; Pu JJ; Beitinjaneh A; Bredeson C; Rizzieri D; Savani BN; Abid MB; Ganguly S; Agrawal V; Ulrike Bacher V; Wirk B; Jain T; Cutler C; Aljurf M; Kindwall-Keller T; Kharfan-Dabaja MA; Hildebrandt GC; Pawarode A; Solh MM; Yared JA; Grunwald MR; Nathan S; Nishihori T; Seo S; Scott BL; Nakamura R; Oran B; Czerw T; Yakoub-Agha I; Saber W
Blood Adv; 2023 Aug; 7(15):3993-4002. PubMed ID: 37134306
[TBL] [Abstract][Full Text] [Related]
16. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Hernández-Boluda JC; Eikema DJ; Koster L; Kröger N; Robin M; de Witte M; Finke J; Finazzi MC; Broers A; Raida L; Schaap N; Chiusolo P; Verbeek M; Hazenberg CLE; Halaburda K; Kulagin A; Labussière-Wallet H; Gedde-Dahl T; Rabitsch W; Raj K; Drozd-Sokolowska J; Battipaglia G; Polverelli N; Czerw T; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2023 Dec; 58(12):1357-1367. PubMed ID: 37679647
[TBL] [Abstract][Full Text] [Related]
18. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.
Polverelli N; Farina M; D'Adda M; Damiani E; Grazioli L; Leoni A; Malagola M; Bernardi S; Russo D
Cells; 2022 Feb; 11(3):. PubMed ID: 35159362
[TBL] [Abstract][Full Text] [Related]
19. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
20. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
